Raife Thomas J
Department of Pathology, C250 GH, University of Iowa Hospitals and Clinics, Iowa City, IA 52242, USA.
Curr Hematol Rep. 2003 Mar;2(2):133-8.
The recent discovery of important molecular and genetic mechanisms of thrombotic thrombocytopenic purpura and hemolytic uremic syndrome provide an opportunity to reconstruct scientific and clinical paradigms. Acquired and congenital defects of the metalloprotease ADAMTS13 are a central feature in the pathogenesis of a major type of thrombotic microangiopathy. This and other pathogenic mechanisms can redefine the terminology of thrombotic microangiopathy. Deficient activity of ADAMTS13 suggests several possible models of microvascular thrombosis. The sporadic relationship between thrombotic microangiopathy and ADAMTS13 deficiency draws attention to other critical pathologic factors that are still poorly understood. Investigation of vascular injury and mechanisms of microvascular thrombosis remain the frontiers of investigation in thrombotic microangiopathy.
血栓性血小板减少性紫癜和溶血性尿毒症综合征重要分子与遗传机制的近期发现,为重构科学和临床范式提供了契机。金属蛋白酶ADAMTS13的获得性和先天性缺陷是一种主要类型血栓性微血管病发病机制的核心特征。这一机制及其他致病机制能够重新定义血栓性微血管病的术语。ADAMTS13活性缺乏提示了几种微血管血栓形成的可能模型。血栓性微血管病与ADAMTS13缺乏之间的散发性关系,使人们关注到其他仍未被充分理解的关键病理因素。血管损伤及微血管血栓形成机制的研究仍是血栓性微血管病研究的前沿领域。